| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/1529-0131(200112)44:12<2870::AID-ART475>3.0.CO;2-Y |
| P698 | PubMed publication ID | 11762948 |
| P50 | author | Pier Luigi Meroni | Q38544871 |
| Raffaella Molteni | Q43160313 | ||
| Angela Tincani | Q73304219 | ||
| Munther A. Khamashta | Q73418907 | ||
| P2093 | author name string | Raschi E | |
| Testoni C | |||
| Tremoli E | |||
| Balestrieri G | |||
| Camera M | |||
| P2860 | cites work | Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate–Phenol–Chloroform Extraction | Q25938986 |
| Atherosclerosis — An Inflammatory Disease | Q26776972 | ||
| Levels of soluble cell adhesion molecules in patients with dyslipidemia | Q28279951 | ||
| NF-kappaB: a key role in inflammatory diseases | Q29617726 | ||
| Simvastatin modulates cytokine-mediated endothelial cell adhesion molecule induction: involvement of an inhibitory G protein | Q31429867 | ||
| Multiple signals converging on NF-kappaB. | Q33597403 | ||
| International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop | Q33685960 | ||
| The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals | Q33688733 | ||
| Premature atherosclerosis in systemic lupus erythematosus | Q33893354 | ||
| Structure-function studies on beta 2-glycoprotein I. | Q34021205 | ||
| Beta 2-glycoprotein I-anti-beta 2-glycoprotein I interaction | Q34021210 | ||
| Which are the best biological markers of the antiphospholipid syndrome? | Q34021258 | ||
| Endothelial activation by aPL: a potential pathogenetic mechanism for the clinical manifestations of the syndrome | Q34021310 | ||
| Experimental thrombosis and antiphospholipid antibodies: new insights | Q34021315 | ||
| Pleiotropic effects of statins. | Q34107414 | ||
| Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors | Q34463540 | ||
| Antiphospholipid antibodies affect trophoblast gonadotropin secretion and invasiveness by binding directly and through adhered beta2-glycoprotein I. | Q36222874 | ||
| HMG-CoA reductase inhibitors for treatment of hypercholesterolemia | Q39645793 | ||
| Immunolocalization of beta2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression | Q40957024 | ||
| 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins | Q41005307 | ||
| Immunology of the antiphospholipid antibody syndrome | Q41116413 | ||
| Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials | Q41535803 | ||
| Chemotaxis of the monocyte cell line U937: Dependence on cholesterol and early mevalonate pathway products | Q41663287 | ||
| Monocyte adhesion and spreading on human endothelial cells is dependent on Rho-regulated receptor clustering | Q42797335 | ||
| Vastatins Inhibit Tissue Factor in Cultured Human Macrophages | Q57398943 | ||
| P433 | issue | 12 | |
| P921 | main subject | antibody | Q79460 |
| endothelium | Q111140 | ||
| P304 | page(s) | 2870-2878 | |
| P577 | publication date | 2001-12-01 | |
| P1433 | published in | Arthritis & Rheumatology | Q4797636 |
| P1476 | title | Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype | |
| P478 | volume | 44 |
| Q84230309 | 8-isoprostane, prostaglandin E2, C-reactive protein and serum amyloid A as markers of inflammation and oxidative stress in antiphospholipid syndrome: a pilot study |
| Q37702168 | A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients |
| Q96304889 | An update on the management of antiphospholipid syndrome |
| Q34981331 | Anti-inflammatory and immunomodulating properties of statins. An additional tool for the therapeutic approach of systemic autoimmune diseases? |
| Q36337932 | Anti-inflammatory effects of statins: clinical evidence and basic mechanisms |
| Q36434227 | Antiendothelial cell antibodies in vasculitis and connective tissue disease |
| Q59808719 | Antiphospholipid Syndrome and the Neurologist: From Pathogenesis to Therapy |
| Q44526752 | Antiphospholipid antibodies affect human endometrial angiogenesis. |
| Q28192380 | Antiphospholipid antibodies in young adults with stroke |
| Q55891386 | Antiphospholipid syndrome |
| Q36458154 | Antiphospholipid syndrome and tissue factor: a thrombotic couple. |
| Q35680777 | Antiphospholipid syndrome infectious origin |
| Q37721617 | Antiphospholipid syndrome treatment beyond anticoagulation: are we there yet? |
| Q38294180 | Antiphospholipid syndrome: 30 years and our contribution |
| Q38410376 | Antiphospholipid syndrome: an update |
| Q35596853 | Association of idiopathic hepatic sinusoidal dilatation with the immunological features of the antiphospholipid syndrome |
| Q52852275 | Atherosclerosis in primary antiphospholipid syndrome. |
| Q36235476 | Atorvastatin, Losartan and Captopril Lead to Upregulation of TGF-β, and Downregulation of IL-6 in Coronary Artery Disease and Hypertension |
| Q37283009 | Autoimmune-mediated atherothrombosis |
| Q35189299 | Cardiac disease in the antiphospholipid syndrome: recommendations for treatment. Committee consensus report |
| Q34081242 | Cardiovascular involvement in autoimmune diseases |
| Q37638376 | Complement activation and pregnancy failure |
| Q37076800 | Controversies in the antiphospholipid syndrome: can we ever stop warfarin? |
| Q38186995 | Diagnosis and management of neuropsychiatric SLE. |
| Q47982275 | Diagnosis and management of the antiphospholipid syndrome |
| Q44663084 | Effects of statins on adhesion molecule expression in endothelial cells |
| Q53190790 | Effects of statins on thrombosis development in patients with systemic lupus erythematosus and antiphospholipid antibodies. |
| Q38782057 | Emerging Therapies in Antiphospholipid Syndrome |
| Q33356831 | Endothelium activation in the anti-phospholipid syndrome |
| Q35172201 | Endothelium as a target for anti-phospholipid antibodies and for therapeutical intervention |
| Q44738348 | Fluvastatin treatment inhibits leucocyte adhesion and extravasation in models of complement-mediated acute inflammation. |
| Q37283020 | Genomics and proteomics: a new approach for assessing thrombotic risk in autoimmune diseases. |
| Q36590359 | Human β2-glycoprotein I attenuates mouse intestinal ischemia/reperfusion induced injury and inflammation |
| Q84274982 | Increase in plasma thrombin-activatable fibrinolysis inhibitor may not contribute to thrombotic tendency in antiphospholipid syndrome because of inhibitory potential of antiphospholipid antibodies toward TAFI activation |
| Q47743642 | Innate immune response gene expression profiles characterize primary antiphospholipid syndrome. |
| Q33369796 | Intravenous immunoglobulin therapy in antiphospholipid syndrome |
| Q38092150 | Management of women with recurrent pregnancy losses and antiphospholipid antibody syndrome |
| Q94154085 | Methotrexate treatment and mortality in rheumatoid arthritis |
| Q90401373 | Microbial Translocation Is Linked to a Specific Immune Activation Profile in HIV-1-Infected Adults With Suppressed Viremia |
| Q57398888 | Modulation of adhesion molecule expression on endothelial cells: to be or not to be? |
| Q37903952 | Molecular pathophysiology of the antiphospholipid syndrome: the role of oxidative post-translational modification of beta 2 glycoprotein I. |
| Q46470748 | More on: fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells |
| Q53063239 | NF-κB is activated from endosomal compartments in antiphospholipid antibodies-treated human monocytes. |
| Q91117776 | Neuropsychiatric lupus: new mechanistic insights and future treatment directions |
| Q90241448 | Neutrophil Extracellular Traps, Antiphospholipid Antibodies and Treatment |
| Q37404485 | New approaches for managing antiphospholipid syndrome |
| Q79288146 | New approaches to prevention of thrombosis in the antiphospholipid syndrome: Hopes, trials, and tribulations |
| Q36998932 | New targeted therapies for treatment of thrombosis in antiphospholipid syndrome |
| Q34140319 | New therapeutic targets for the antiphospholipid syndrome |
| Q51821388 | Pathogenesis and management of antiphospholipid syndrome. |
| Q36666808 | Pathogenic mechanisms of anti-endothelial cell antibodies (AECA): their prevalence and clinical relevance. |
| Q36671159 | Pathophysiological mechanisms in antiphospholipid syndrome |
| Q33511345 | Plasma gelsolin facilitates interaction between β2 glycoprotein I and α5β1 integrin |
| Q37959316 | Potential use of statins in the treatment of antiphospholipid syndrome. |
| Q37812011 | Primary Thrombosis Prophylaxis in Antiphospholipid Antibody–Positive Patients: Where Do We Stand? |
| Q35189302 | Probing antiphospholipid-mediated thrombosis: the interplay between anticardiolipin antibodies and endothelial cells |
| Q64120268 | Role of TLR‑4 in anti‑β2‑glycoprotein I‑induced activation of peritoneal macrophages and vascular endothelial cells in mice |
| Q39931228 | Role of apolipoprotein B100 and oxidized low-density lipoprotein in the monocyte tissue factor induction mediated by anti-β2 glycoprotein I antibodies |
| Q34676688 | Role of tissue factor in thrombosis in antiphospholipid antibody syndrome |
| Q38097749 | Statins and autoimmunity |
| Q36695979 | Statins and the vascular endothelial inflammatory response |
| Q38844621 | Stroke in systemic lupus erythematosus and antiphospholipid syndrome: risk factors, clinical manifestations, neuroimaging, and treatment |
| Q38945325 | The ERK1/2 pathway participates in the upregulation of the expression of mesenteric artery α1 receptors by intravenous tail injections of mmLDL in mice |
| Q37154882 | The enigmas of the lupus anticoagulant: mechanisms, diagnosis, and management |
| Q37909189 | The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in rheumatologic disorders: a comprehensive review |
| Q37283046 | Tissue factor in the antiphospholipid syndrome |
| Q36013878 | Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies |
| Q38135335 | Top 10 clinical research developments in antiphospholipid syndrome |
| Q38149851 | Transient ischemic attack and stroke in systemic lupus erythematosus |
| Q28193706 | Treatment and monitoring of patients with antiphospholipid antibodies and thrombotic history (Hughes syndrome) |
| Q35621012 | Treatment of Thrombotic Antiphospholipid Syndrome: The Rationale of Current Management-An Insight into Future Approaches |
| Q38755260 | Treatment of catastrophic antiphospholipid syndrome |
| Q38591752 | Why are kids with lupus at an increased risk of cardiovascular disease? |
| Q35001052 | Why might statins prevent venous thromboembolism: what needs to be done to know more? |
| Q84600032 | [Antiphospholipid syndrome treatment, to whom, when and how long?] |
Search more.